



ORIGINAL ARTICLE

Heart and brain interactions in heart failure: Cognition, depression, anxiety, and related outcomes



Joana Rigueira^{a,b,*}, João R. Agostinho^{a,b,1}, Inês Aguiar-Ricardo^{a,b},
 Inês Gonçalves^{a,b}, Rafael Santos^{a,b}, Afonso Nunes-Ferreira^{a,b}, Tiago Rodrigues^{a,b},
 Nelson Cunha^{a,b}, N'Zinga André^a, Raquel Pires^c, Fátima Veiga^a,
 Mónica Mendes Pedro^{a,b}, Fausto J. Pinto^{a,b}, Dulce Brito^{a,b}

^a Serviço de Cardiologia, Departamento de Coração e Vasos, Centro Hospitalar Universitário de Lisboa Norte, Lisboa, Portugal

^b Centro Académico de Medicina de Lisboa (CAML), Centro Cardiovascular da Universidade de Lisboa, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisboa, Portugal

^c Faculdade de Psicologia, CINEICC, Universidade de Coimbra, Coimbra, Portugal

Received 24 March 2020; accepted 16 September 2020

KEYWORDS

Heart failure;
 Cognitive function;
 Anxiety;
 Depression;
 Prognosis;
 Quality of life

Abstract

Background: Cognitive impairment, anxiety and depression are common in heart failure (HF) patients and its evolution is not fully understood.

Objectives: To assess the cognitive status of HF patients over time, its relation to anxiety and depression, and its prognostic impact.

Methods: Prospective, longitudinal, single center study including patients enrolled in a structured program for follow-up after hospital admission for HF decompensation. Cognitive function, anxiety/depression state, HF-related quality of life (QoL) were assessed before discharge and during follow-up (between 6th and 12th month) using Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS) and Kansas City Cardiomyopathy Questionnaire, respectively. HF related outcomes were all cause readmissions, HF readmissions and the composite endpoint of all-cause readmissions or death.

Results: 43 patients included (67±11.3 years, 69% male); followed-up for 8.2±2.1 months. 25.6% had an abnormal MoCA score that remained stable during follow-up (22.6±4.2 vs. 22.2±5.5; p=NS). MoCA score <22 at discharge conferred a sixfold greater risk of HF readmission [HR=6.42 (1.26-32.61); p=0.025], also predicting all-cause readmissions [HR=4.00 (1.15-13.95); p=0.03] and death or all-cause readmissions [HR=4.63 (1.37-15.67); p=0.014]. Patients with higher MoCA score showed a greater ability to deal with their disease (p=0.038). At discharge, 14% and 18.6% had an abnormal HADS score for depression and anxiety, respectively, which remained stable during follow-up and was not related to MoCA.

* Corresponding author.

E-mail address: joana.rigueira@gmail.com (J. Rigueira).

¹ J.R. and J.R.A. are both first authors in the manuscript.

Conclusions: Cognitive function, anxiety and depressive status remain stable in HF patients despite optimized HF therapy. Cognitive status shall be routinely screened to adopt attitudes that improve management as it has an impact on HF-related QoL and prognosis.

© 2021 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALAVRAS-CHAVE

Insuficiência cardíaca;
Funcionamento cognitivo;
Ansiedade;
Depressão;
Prognóstico;
Qualidade de vida

Interações entre o coração e o cérebro na insuficiência cardíaca: cognição, depressão, ansiedade e *outcomes* relacionados

Resumo

Introdução: A disfunção cognitiva, ansiedade e depressão são comuns nos doentes com insuficiência cardíaca (IC) e a sua evolução não é integralmente conhecida.

Objetivos: Avaliar o estado cognitivo dos doentes com IC ao longo do tempo, a sua relação com ansiedade/depressão e o seu impacto prognóstico.

Métodos: Estudo prospetivo, longitudinal, unicêntrico de doentes seguidos num programa estruturado após internamento por IC descompensada. A função cognitiva, estado ansioso/depressivo, qualidade de vida (QV) relacionada com a IC foram avaliadas antes da alta e durante o seguimento (entre 6.º-12.º mês) utilizando o *Montreal Cognitive Assessment* (MoCA), a *Hospital Anxiety and Depression Scale* (HADS) e o *Kansas City Cardiomyopathy Questionnaire* (KCCQ), respetivamente. Avaliaram-se *outcomes* relacionados com IC: reinternamento por qualquer causa, reinternamentos por IC e objetivo composto de morte/reinternamento.

Resultados: Foram incluídos 43 doentes ($67\pm 11,3$ anos, 69% homens); seguidos por $8,2\pm 2,1$ meses. 25,6% tinham um resultado anormal no MoCA que se manteve estável no seguimento ($22,6\pm 4,2$ versus $22,2\pm 5,5$; $p=NS$). Um resultado do MoCA <22 na alta conferiu um risco seis vezes superior de reinternamento por IC [HR=6,42 (1,26-32,61); $p=0,025$], sendo também preditor de reinternamento por qualquer causa [HR=4,00 (1,15-13,95); $p=0,03$] e do objetivo composto [HR=4,63 (1,37-15,67); $p=0,014$]. Doentes com um resultado mais elevado no MoCA apresentaram maior capacidade para lidar com a IC ($p=0,038$). Na alta, 14% e 18,6% tinham um resultado anormal no HADS para a depressão e ansiedade, respetivamente, que se manteve estável no seguimento e não se associou ao MoCA.

Conclusões: O funcionamento cognitivo e o estado ansioso/depressivo mantêm-se estáveis apesar da terapêutica otimizada para a IC. Tendo impacto na QV relacionada com a IC e no prognóstico, a função cognitiva deverá ser rastreada por rotina para adotar atitudes que melhorem a abordagem a estes doentes.

© 2021 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Heart failure (HF) is a major public health problem affecting globally 1-2% of the adult population in developed countries, and more than 10% of those >70 years-old.¹⁻³ Despite the advances in therapy in recent decades, HF is associated with high mortality and morbidity, especially recurrent hospitalizations, and reduced functional status and quality of life (QoL).^{1,4} Given the aging population, the overall prevalence of the syndrome is expected to rise in the near future.^{3,4}

Heart failure is a complex syndrome, not limited to the heart itself, but involving whole body systems, including the central nervous system. Brain-heart involvement is believed to be bidirectional and diverse interactions (some still misunderstood), between cardiac and cerebral function may lead to cognitive impairment, anxiety and depression,^{5,6} which in turn can contribute to further

deterioration of HF. Cognitive function is essential to understand information, to learn and recall specific knowledge, and these skills are used to solve problems and plan actions in the challenges posed by everyday life. Anxiety and depression are also common in association with HF and contribute to morbidity and increased healthcare use.^{5,7} Anxiety and depression seems to contribute to abnormal cognitive status⁸ in patients with other chronic diseases,⁹ however the simultaneous assessment of anxiety, depression and cognitive impairment (CI) in HF patients was poorly studied.¹⁰⁻¹²

The high prevalence of cognitive impairment in HF patients is already recognized,^{5,13} ranging from 25% to 75%,^{5,13} but there is limited knowledge of the evolution of cognitive status over time in these patients.¹⁴ In addition, some of the published longitudinal studies include patients enrolled more than 10 years ago,¹⁴⁻¹⁹ prior to significant changes in HF treatment strategies. Furthermore, some

studies reveal contradictory results in what concerns cognitive status over time.^{13,20} Those performed by Riegel et al.,²¹ Alosco et al.²² and Stanek et al.,¹⁹ who studied HF patients' cognition with a battery of neuropsychological tests, found both stability and/or improvement in cognitive testing over time; however other authors²³ reported decreased cognitive function over time in HF patients.

The aim of this study was to assess, in a population HF followed accordingly to a structured HF program and under optimized therapy, global cognitive status over time, its association with anxiety and/or a depressive state, and to assess the prognostic impact of this condition on HF outcomes (all-cause readmissions, HF readmissions and the composite endpoint of death or readmission). To our knowledge, this is the first study with longitudinal data that simultaneously investigated cognitive status, anxiety and depression in Portuguese patients with HF followed-up in accordance with optimal recommended practices.¹

Methods

Setting, study design and patient selection criteria

A prospective, single center study conducted at a tertiary hospital (Cardiology Department, Hospital Universitário de Santa Maria, Lisbon, Portugal).

All adult patients (≥ 18 years-old), consecutively admitted (index-admission) to the cardiology ward with acute HF (*de novo* or chronic decompensated HF), defined according to criteria in the Guidelines of the European Society of Cardiology (ESC),¹ were potentially eligible for inclusion in a post-discharge follow-up HF-program (by protocol), after written informed consent was obtained. This structured post-discharge follow-up program has already been described elsewhere.²⁴ Specific and validated questionnaires for assessment of QoL, and evaluation of cognitive status and depression and chronic anxiety states by application of specific and validated questionnaires at pre-specified times, are components of the program. Patients with language barriers (unable to speak and/or understand Portuguese), visual and auditory deficits, and previously diagnosed neurological or psychiatric disease were excluded from the present study.

Screening procedures

Cognitive status, chronic anxiety and depression, were screened at hospital discharge, when the patients were stable, to reduce a possible confounder related to disease decompensation and hospitalization, and between the 6th and the 12th month after discharge.

The most recent ESC Guidelines for the diagnosis and treatment of acute and chronic HF¹ stated that cognitive function can be assessed using the Mini-Mental State Examination (MMSE)²⁵ or the Montreal Cognitive Assessment (MoCA).²⁶ In this study the validated Portuguese version of the MoCA was used. It is a cognitive screening instrument with greater sensitivity than the MMSE to milder stages of cognitive decline.³¹ It is a one-page test with a maximum score of 30 points, which defines CI according to a score of < 22 (cut-off validated for the Portuguese population),^{28,29}

assessing eight cognitive domains: executive functions; visuospatial abilities; short-term memory; language; attention, concentration, and working memory; temporal and spatial orientation.^{26,30}

The MoCA score was assessed as a continuous variable to compare evolution over time and as a dichotomous variable based on a cutoff score of 22 to distinguish patients with a normal versus an abnormal score.

Chronic anxiety and depression were assessed using the validated Portuguese version of the Hospital Anxiety and Depression Scale (HADS).²⁷ The HADS is composed of seven questions relevant to either generalized anxiety or depression, with each item containing a four-point (0-3) response category. The possible scores range from 0 to 21 for anxiety and the same for depression. Anxiety and depression should be scored separately. A score of 0 to 7 for either subscale can be regarded as being in the normal range, a score of 8 to 10 suggests a borderline case, and a score of 11 to 21 suggests an abnormal case.³²⁻³⁴

The validated Portuguese version of the Kansas City Cardiomyopathy Questionnaire (KCCQ), a responsive health-related QoL measure for HF, was also used.³⁰ The KCCQ is a 23-item, self-administered instrument that quantifies two main domains composed of multiple subdomains: symptoms (physical function and symptoms frequency, severity and recent change), and global QoL (social function, self-efficacy and knowledge and quality of life). Scores are transformed to a range of 0-100, in which higher scores reflect a better health status.^{35,36}

The KCCQ was answered at hospital discharge (referring to the QoL status previous to hospital admission), and during follow-up at three months and between the 6th and the 12th month after discharge.

Demographic and clinical data, including laboratory values, echocardiography and electrocardiography results, and other instrumental data were collected from the patient's clinical file.

Prognostic outcomes were assessed as a composite endpoint of all-cause readmissions or mortality and individual endpoints of all-cause readmissions and HF readmissions. The association of CI with QoL was also evaluated. The occurrence of death and rehospitalization and the cause of rehospitalization were identified based on the information available in the clinical records.

Statistical analysis

Statistical analysis was performed using IBM® SPSS® Statistics 20 (Chicago, IL, United States). Categorical variables were reported in absolute numbers and percentage and continuous variables were reported as mean and standard deviation (SD) or median and interquartile range. The impact of cognitive status on endpoints was assessed using the statistical methods of Cox Regression and Kaplan-Meier survival analysis. Anxiety and depressive status were used as covariates and included together with cognitive status (evaluated by MoCA and HADS questionnaires) on multivariate analyses (adjusted for age, left ventricle ejection fraction (LVEF) and NYHA functional class at discharge). Wilcoxon's test was used to evaluate MoCA value variation during follow-up. $P < 0.05$ was considered statistically significant.

Ethical considerations

The study was approved by the Institutional Ethics Committee and by the National Committee on Data Protection. Patient confidentiality was ensured through the anonymization of the collected data and written informed consent was obtained from all patients before enrolment. All study procedures were carried out in accordance with the ethical principles of the 2013 revised version of the Declaration of Helsinki.³⁷

Results

Baseline data

A total of 43 patients were included in the present study. The mean follow-up period was 8.2±2.1 months. Patient demographic and clinical characteristics at baseline are described in Table 1. Mean age was 67±11.3 years and 31 patients (68.9%) were male. The most frequent HF etiology was idiopathic dilated cardiomyopathy (55.8%), followed by ischemic heart disease (23%). Comorbidities (systemic hypertension, chronic kidney disease, atrial fibrillation and diabetes) were highly prevalent.

The median LVEF assessed by transthoracic echocardiography was 30.3±12.5%, and 37 (86%) patients had HF with reduced ejection fraction (HFrEF). Prior to index-hospitalization, 25 patients (58%) were on treatment with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), 25 (58%) with a beta-blocker and 10 (23%) with a mineralocorticoid receptor antagonist. Index-hospitalization was the first HF admission for 17 patients (39.5%). Nearly half of the patients (48.8%) were in NYHA functional class III on admission and 95% were discharged in NYHA functional class I or II. The mean length of stay was 14.6±16.9 days. Neurohormonal modulation therapy was successfully initiated and/or up-titrated during the hospital stay and optimized treatment (drugs, and devices if indicated) was attempted in all patients during follow-up. The mean score on MoCA at-discharge was 22.6±4.2 and 11 patients (25.6%) had an abnormal score affecting mainly the cognitive domains of visuospatial/executive capacity, language and delayed recall (Table 2, Figure 1).

A better performance on MoCA score at discharge was achieved by the male population (p=0.026) and by patients on ACEi or ARB prior to the index-hospitalization (p=0.009).

At discharge, six patients (14%) had an abnormal HADS for depression, 12 patients (27.9%) obtained a borderline value, and 25 patients (58%) had a normal score.

Regarding HADS for anxiety, 24 patients (55.8%) had a normal score at discharge, 11 patients (25.6%) had a borderline score, and 8 (19%) had an abnormal score.

Neither depression nor anxiety screened by HADS was associated with an abnormal MoCA score.

Follow-up data

Follow-up clinical data are detailed in Table 3. When comparing the results of the MoCA scores at baseline and at the

Table 1 Demographic and clinical data of the study population at baseline.

Age - years (mean±SD)	67±11.3
Male gender- n (%)	31 (68.9)
Patients with <12 years of education - n (%)	28 (65.1)
HF etiology - n (%)	
Ischemic heart disease	10 (23.3)
Valvular heart disease	5 (11.6)
Idiopathic dilated cardiomyopathy	24 (55.8)
Hypertrophic cardiomyopathy	2 (4.7)
Restrictive/infiltrative cardiomyopathy	1 (2.3)
Other	1 (2.3)
NYHA - on admission - n (%)	
I	0
II	2 (4.7)
III	21 (48.8)
IV	20 (46.5)
NYHA - at discharge - n (%)	
I	12 (27.9)
II	29 (67.4)
III	2 (4.7)
IV	0 (0)
LVEF (mean±SD) at discharge	30.3±12.5%
HFrEF (n (%))	37(86%)
HFmrEF (n (%))	3 (7%)
HFpEF (n (%))	3 (7%)
Comorbidities- n (%)	
Diabetes	14 (32.6)
Systemic hypertension	31 (72.1)
Chronic kidney disease (eGFR<60ml/min)	18 (41.9)
Atrial fibrillation	24 (55.8)
Blood pressure at discharge (mean)	
Systolic blood pressure	107 mmHg
Diastolic blood pressure	59 mmHg
HF therapy prior to admission - n (%)	
ACEi/ARB	25 (58.1)
Beta-blocker	25 (58.1)
MRA	10 (23.3)
Sacubitril-valsartan	0 (0)
CRT	9 (20.9)
Laboratory plasma or serum values (median) on admission	
NTproBNP	4222 pg/mL
Serum creatinine	1.0 mg/dL
Hemoglobin	14.0 g/dL
HbA1c	6.0%
Total bilirubin	1.0 mg/dL

ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CRT: cardiac resynchronization therapy; eGFR: estimated glomerular filtration rate (by CKD-EPI creatinine equation); HbA1C: Hemoglobin A1C; HF: heart failure; HFrEF: HF with reduced LVEF; HFmrEF: HF with LVEF in the median range; HFpEF: HF with preserved LVEF; LVEF: left ventricular ejection fraction; MRA: mineralocorticoid receptor antagonist; NT-proBNP: N terminal proB-type natriuretic peptide; NYHA: New York Heart Association functional class.

Table 2 Cognitive domains – individual scores of the study population.

Cognitive domain	Baseline (at discharge)		Follow-up		P
	Mean score (% of attainable total)	Number of patients with maximum score	Mean score (% of attainable total)	Number of patients with maximum score	
Visuospatial/executive	63.2±26.1	7 (16.3%)	62.9±25.4	8 (18.6%)	0.34
Naming	97.4±9.0	40 (93.0%)	90.5±17.8	32 (74.4%)	0.031
Attention	82.5±22.2	16 (37.2%)	79.8±28.1	22 (51.2%)	0.081
Language	70.3±27.7	22 (51.2%)	75.0±23.4	17 (39.5%)	0.079
Abstraction	79.0±34.2	14 (32.6%)	76.8±31.9	26 (60.5%)	0.78
Delayed recall	46.8±32.3	2 (4.7%)	55.7±26.8	3 (7.0%)	0.27
Orientation	94.7±8.8	31 (72.1%)	92.3±17.3	34 (79.1%)	0.18




Figure 1 Examples of patient performance in assessing visuospatial executive domain (A: Copy the cube; B: Complete the sequence; C: Draw a clock: 11:10).

follow-up evaluations, no significant difference was found (mean scores: 22.6±4.2 vs. 22.2±5.5; p=non-significant [NS]), and the total number of patients with an abnormal score was also similar (11 (25.6%) vs. 10 (23.3%); p=NS). However, a significant reduction in the naming ability domain was observed during follow-up (97.4±9.0% vs. 90.5±17.8%; p=0.031) but this result was not considered clinically relevant (Table 2).

The mean HADS for depression and anxiety did not change significantly during follow-up (6.7±4.0 vs. 5.63±4.5; p=0.137; 6.98±4.4 vs. 6.57±4.4; p=0.624, respectively). However, some individual variation was found. During follow-up, 29 (67.4%) patients had a normal HADS for depression, 9 (20.9%) a borderline value and 5 (11.6%) an abnormal score; and 28 (65.1%) patients had a normal HADS for anxiety, 9 (20.9%) a borderline value and 6 (14.0%) an abnormal score (Figure 2).

Influence of cognitive status in heart failure outcomes

During follow-up, one patient died (2.33%), 14 (32.6%) patients were readmitted (20.9% due to HF) and 15 (34.9%) patients had the composite endpoint of all-cause

rehospitalization and/or mortality. The presence of mild CI at discharge (reflected by a MoCA <22) was highly predictive of adverse events during the follow-up period: in a multivariate analysis a MoCA score <22 (vs. ≥22) at discharge increases sixfold the risk of HF readmissions (HR=6.42 [1.23-32.61]; p=0.025) (Figure 3A). Also, the presence of CI was an independent predictor of all-cause readmissions (Hazard ratio [HR]=4.00 (1.15-13.95); p=0.03) (Figure 3B) and conferred an almost five fold greater risk of the composite endpoint of all-cause readmission or death (HR=4.63 [1.37-15.67]; p=0.014) (Figure 3C).

There was no significant difference in KCCQ main domains (symptoms and global QoL) when comparing patients with vs. without CI (65.1±26.3% vs. 64.9±25.2%; p=NS; 60.5±18.4% vs. 64.4±19.4%; p=NS, respectively), but patients with a higher MoCA score performance at discharge, and therefore with better cognitive status, had a better ability to deal with their HF according to the assessment of this component in the KCCQ (p=0.038).

Discussion

To our knowledge this is the first longitudinal study performed in a cohort of Portuguese patients with HF that

Table 3 Clinical data of the study population at follow-up.

NYHA - n (%)	
I	31 (72.09)
II	10 (23.4)
III	1 (2.33)
IV	1 (2.33)
LVEF (mean±SD)	
LVEF<40% (n (%))	19 (44.2%)
LVEF between 40-49% (n (%))	14 (32.6%)
LVEF>50% (n (%))	10 (23.3%)
Blood pressure (mean)	
Systolic blood pressure	109 mmHg
Diastolic blood pressure	61 mmHg
HF therapy - n (%)	
ACEi/ARB/sacubitril-valsartan	43 (100)
Beta-blocker	40 (93.0)
MRA	35 (81.4)
CRT	9(20.9)
Laboratory plasma or serum values (median)	
NTproBNP	1620 pg/mL
Serum creatinine	1.0 mg/dL
Hemoglobin	14.0 g/dL
HbA1c	6.0%
Total bilirubin	1.0 mg/dL

ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CRT: cardiac resynchronization therapy; HbA1C: Hemoglobin A1C; HF: heart failure; LVEF: left ventricular ejection fraction; MRA: mineralocorticoid receptor antagonist; NT-proBNP: N terminal proB-type natriuretic peptide; NYHA: New York Heart Association functional class.




Figure 2 Hospital Anxiety and Depression Scale variation over the time for depression (A) and anxiety (B). Legend: HADS: Hospital Anxiety and Depression Scale.




Figure 3 Kaplan-Meier curves for (A) HF hospital readmission, (B) all-cause readmission, and (C) the composite endpoint of all-cause readmission or death, according to the Montreal Cognitive Assessment score.

assessed cognitive status simultaneously with anxiety and depression, its variation and prognostic impact after hospital discharge, when followed-up according to a dedicated and structured HF program.

Moreover, this study adds information to previous published data regarding the evolution of cognitive status, anxiety and depressive status (assessed with simple-to-apply although recommended screening tools) in a group of patients managed according to the most recent recommendations for HF treatment. According to our findings, cognitive status, anxiety and depression remained stable

over almost one year of follow-up under optimized HF therapy; mild CI had significant impact on the patient's prognosis and poorer quality of life. Specific contributions are discussed in the following paragraphs.

The presence of CI in the HF population is well documented in literature,^{38,39} with most studies including patients with heart failure with reduced ejection fraction. Higher prevalence is observed in patients with more severe symptoms and need for hospitalization.^{40–43} Our population, showing a significant rate (26%) of mild CI, fits this profile, as 86% had HF_{rEF}, all were discharged from hospital after an episode of HF decompensation, and 60% had previous hospitalizations for HF.

Although this association between CI and HF has been well documented in the literature, with HF patients presenting a twofold increased risk of impaired cognitive function compared with age-matched controls,²⁰ the understanding of the time course of cognitive change in HF is limited.^{14,20} Few studies have examined longitudinal neurocognitive outcomes in HF¹⁹ and their results are contradictory,²⁰ with some studies showing an improvement in cognitive status over time, while others document a deterioration, or that cognitive state remains stable. Our study helps to clarify this controversial topic.

First, we present a study with longitudinal design that shows a minimal improvement in cognitive performance (from 26% to 23% of patients with CI, not statistically significant) assessed with a screening tool (MoCA score) during follow-up. This result is in line with Riegel et al.'s study that included a higher number of patients (n=279) with chronic HF followed with a battery of neuropsychological tests at baseline over a similar period of time (three and 6 months), and where the average digit symbol substitution task scores improved minimally from 53.4±17.5 at baseline, to 55.8±17.6 at three months, and to 58.1±17.9 at six months.²¹

Others^{14,16,19} have found significant improvements in cognition over time. However, those patients had higher LVEF and were assessed at different stages of HF decompensation, therefore different patient profiles and settings might explain the different results. In addition, other studies that compared patient follow-up scores on cognitive tests with their baseline scores and tended to report significant improvements in cognitive performance over time, usually show significant improvements in cardiac parameters as a result of treatments or interventions tested in the study,^{44–47} or a different design to our study which is just observational. This association was most evident in studies documenting dramatic improvements in cardiac function, such as those assessing heart transplantation recipients.^{20,21,46,47}

As previously mentioned, there is no consensus on this topic, as other previous studies reported decreased cognitive function over time in HF patients.²³ Almeida et al. studied 77 adults with HF (defined by LVEF<40%) with a battery of neuropsychological tests (Cambridge Cognitive Examination of the Elderly (CAMCOG) and found that HF patients showed evidence of cognitive decline over two years compared with controls with normal left ventricular function; again a study with a different design and with a longer follow-up.

To sum up, we can put forward some hypotheses to explain our results: first, our follow-up of eight months

might be too short to show significant changes in the cognitive status; second, although the recommended HF therapy improves the prognosis in these patients, it may not have had impact on some of the mechanisms of CI in HF, particularly on the deranged self-regulation of brain vessels and metabolism and on the systemic inflammatory and hypercoagulability states associated with HF; and finally, CI might represent an irreversible impairment in some patients, and optimal medical therapy may only contribute to stabilization, preventing its worsening.

Second, we found a significant impact of cognitive status on HF patient prognosis, even when assessed with a screening tool. The presence of CI (assessed by an abnormal MoCA score) at discharge conferred a fivefold greater risk of the composite endpoint of all-cause readmissions or death, increasing by four times the risk of hospital readmission and by six the risk of HF readmission. Also, patients with a better MoCA score performance at discharge, reflecting a better cognitive status, were better placed to deal with their heart disease. The results regarding outcomes are in line with those observed in several previous larger studies⁴⁸ showing a strong independent association of CI with increased mortality and readmissions in HF patients,^{10,49–52} even in cases of only mild CI^{10,50} that often remain undiagnosed. However, despite its recognized prevalence and negative prognostic impact, HF guidelines relating to cognitive assessment^{1,53} are scarce and no standardized procedures for assessment and management are specifically recommended.

Finally, in what concerns depression and anxiety, our study also adds to previous studies the simultaneous evaluation (easily feasible) of cognitive function, depression and anxiety (the latter very rarely studied in this population) over time in HF patients, co-morbidities with an already known relevant impact on prognosis and quality of life in these patients.¹¹

In our study more than 40% of the patients had altered HADS result, reflecting, as previously described, that anxiety and depression are common comorbidities in HF patients.⁵⁴ However, contrary to others,⁵⁴ we found that these comorbidities were not associated with cognitive status. There are however some contradictory results, with some studies presenting data similar to ours.⁴⁰

In this study, both depression and anxiety remain stable during follow-up. This is a relevant information as, even though they are common in these patients, these comorbidities, especially anxiety, are poorly studied in HF.

Limitations and strengths

The authors recognize some limitations in their work, including the fact that this study was from a single center and included only 43 patients, which may also compromise the statistical analysis in a model with several covariates. However, this represents real-world practice including an HF population admitted to hospital due to acute HF and followed-up prospectively in an outpatient HF clinic setting. The observed data on rates of cognitive impairment, anxiety and depression were similar to those obtained in studies with larger HF populations. It is plausible that the 8±2 month period of follow-up may not have been long enough to capture changes in cognitive performance in HF even with

therapeutic optimization, however, some of the previously published studies have similar or shorter follow-up.²⁰ Similar studies with a longer follow-up are needed. Another concern is the possibility of false positives and negatives in MoCA and HADS results. Also, although patients with previously diagnosed neurological or psychiatric disease were excluded, brain imaging studies were not routinely performed, so the presence of chronic brain lesions that might contribute to our results cannot be fully ruled out. Nevertheless, no patients had evidence of neurologic deficits, either at inclusion or during the follow-up period.

It is also important to note that most of the previous published studies on the prognostic impact of CI in HF used batteries of neuropsychological tests instead of screening tools.⁷ Although neuropsychological tests provide information about function across multiple domains and have diagnostic acuity, their application usually takes several hours and requires specialized training in the instruments and interpreting them.⁵⁵ Cannon et al.⁷ previously recommended an increasing use of cognitive assessment with standardized screening tools in all future HF studies. These cognitive screening tools provide initial insight into an individual's cognitive status and assist with a decision for referral for more comprehensive neuropsychological testing where the presence of CI will be determined.

Conclusion

The course of cognitive change in HF is not completely understood. According to our study and in keeping with previously published works, at the moment it does not appear that the cognitive performance of HF patients greatly improves over time. Our study contributes to support the findings of previous studies on a controversial subject, indicating further areas for future investigation on this issue.

This study helps to draw attention to the significant rates of abnormal cognitive status in Portuguese HF patients which correlates with poor long-term prognosis, even in patients who are managed in accordance with best practices. These results also emphasize the need for the early identification of these conditions and underline the importance of making health professionals aware of this reality, which may lead to a more individualized approach with potential prognostic benefits.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2016;37:2129–200.
- Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. *Nat Rev Cardiol*. 2011;8:30–41.
- Heidenreich PA, Chair F, Albert NM, et al. Forecasting the Impact of heart failure in the United States: a policy statement from the American Heart Association Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Stroke C. *Circ Hear Fail [Internet]*. 2013;6:606–19.
- Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: preventing disease and death worldwide. *ESC Hear Fail*. 2014;1:4–25.
- Doehner W, Ural D, Haeusler KG, et al. Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. *Eur J Heart Fail*. 2018;20(February):199–215.
- Kim MS, Kim JJ. Heart and brain interconnection – clinical implications of changes in brain function during heart failure. *Circ J*. 2015;79:942–7.
- Cannon JA, McMurray JJV, Quinn TJ. ‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure. *Alzheimer’s Res Ther*. 2015;7:1–18.
- John A, Patel U, Rusted J, et al. Affective problems and decline in cognitive state in older adults: a systematic review and meta-analysis. *Psychol Med*. 2019;49:353–65.
- Whitehouse CE, Fisk JD, Bernstein CN, et al. Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. *Neurology*. 2019;92:E406–17.
- Huynh QL, Negishi K, Blizzard LS, et al. Mild cognitive impairment predicts death and readmission within 30 days of discharge for heart failure. *Int J Cardiol [Internet]*. 2016;221:212–7.
- Sokoreli I, Pauws SC, Steyerberg EW, et al. Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study. *Eur J Hear Fail*. 2018:1–8.
- Almeida OP, Garrido GJ, Etherton-beer C, et al. Brain and mood changes over 2 years in healthy controls and adults with heart failure and ischaemic heart disease. *Eur J Heart Fail*. 2013;15:850–8.
- Leto L, Feola M. Cognitive impairment in heart failure patients. *J Geriatr Cardiol*. 2014;11:316–28.
- Hammond CA, Blades NJ, Chaudhry SI, et al. Long-term cognitive decline after newly diagnosed heart failure. *Circ Hear Fail*. 2018;11:1–11.
- Karlsson MR, Edner M, Henriksson P, et al. A nurse-based management program in heart failure patients affects females and persons with cognitive dysfunction most. *Patient Educ Couns*. 2005;58:146–53.
- Almeida, Osvaldo PST. Clinical treatment reverses attentional deficits in congestive heart failure. *BMC Geriatr*. 2001;1.
- Zuccalà G, Marzetti E, Cesari M, et al. Correlates of cognitive impairment among patients with heart failure: results of a multicenter survey. *Am J Med*. 2005;118:496–502.
- Qiu C, Winblad B, Marengoni A, et al. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. *Arch Intern Med*. 2006;166(May):1003–8.
- Stanek KM, Gunstad J, Paul RH, et al. Longitudinal cognitive performance in older adults with cardiovascular disease: evidence for improvement in heart failure. *J Cardiovasc Nurs*. 2009;24:192–7.
- Hajduk AM, Kiefe CI, Person SD, et al. Cognitive change in heart failure: a systematic review. *Circ Cardiovasc Qual Outcomes*. 2013;6:451–60.
- Riegel B, Lee CS, Glaser D, et al. Patterns of change in cognitive function over six months in adults with chronic heart failure. *Cardiol Res Pract*. 2012;1.
- Alosco ML, Garcia S, Spitznagel MB, et al. Cognitive performance in older adults with stable heart failure: longitudinal evidence for stability and improvement. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn*. 2014;21:1–18.
- Almeida OP, Beer C, Lautenschlager NT, et al. Two-year course of cognitive function and mood in adults with congestive heart failure and coronary artery disease: the Heart-Mind Study. *Int Psychogeriatrics*. 2012;24:38–47.

24. Agostinho JR, Gonçalves I, Rigueira J, et al. Protocol-based follow-up program for heart failure patients: Impact on prognosis and quality of life. *Rev Port Cardiologia*. 2019;38:755-64.
25. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12:189-98.
26. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005.
27. Cameron J, Kure CE, Pressler SJ, et al. Diagnostic accuracy of cognitive screening instruments in heart failure: a systematic review. *J Cardiovasc Nurs*. 2015;31:412-24.
28. Freitas S, Simões MR, Alves L, et al. Montreal cognitive assessment – validation study for mild cognitive impairment and alzheimer disease. *Alzheimer Dis Assoc Disord*. 2013;27:37-43.
29. Freitas S, Simões MR, Santana I. Montreal Cognitive Assessment (MoCA): pontos de corte no défice cognitivo ligeiro, doença de alzheimer, demência frontotemporal e demência vascular. *Sinapse*. 2014;14-28:18.
30. Freitas S, Simões MR, Martins C, et al. Estudos de adaptação do Montreal Cognitive Assessment (MoCA) para a população portuguesa [Montreal Cognitive Assessment (MoCA): Portuguese adaptation studies]. *Aval Psicol*. 2010;9:345-57.
31. Cameron J, Worrall-Carter L, Page K, et al. Screening for mild cognitive impairment in patients with heart failure: Montreal Cognitive Assessment versus Mini Mental State Exam. *Eur J Cardiovasc Nurs*. 2013;12:252-60.
32. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand*. 1983;67:361-70.
33. Pais-Ribeiro J, Silva I, Ferreira T, et al. Validation study of a Portuguese version of the Hospital Anxiety and Depression Scale. *Psychol Health Med*. 2007;12(March):225-35.
34. Stern AF. The Hospital Anxiety and Depression Scale. *Occup Med (Chic Ill)*. 2014;64(July):393-4.
35. Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure. *J Am Coll Cardiol*. 2000;35:1245-55.
36. Nave-Leal E, Pais-Ribeiro J, Oliveira MM, et al. Psychometric properties of the portuguese version of the Kansas City cardiomyopathy questionnaire in dilated cardiomyopathy with congestive heart failure. *Rev Port Cardiol*. 2010;29(March):353-72.
37. World Medical Association. World Medical Association Declaration of Helsinki Ethical principles for medical research involving human subjects. *JAMA*. 2013;310:2191-4.
38. Athilingam P, D'Aoust RF, Miller L, et al. Cognitive profile in persons with systolic and diastolic heart failure. *Congest Hear Fail*. 2013;19:44-50.
39. Čelutkienė J, Vaitkevičius A, Jakštieņe S, et al. Cognitive decline in heart failure: more attention is needed. *Card Fail Rev*. 2016.
40. Pressler SJ, Subramanian U, Kareken D, et al. Cognitive deficits in chronic heart failure. *Nurs Res*. 2010;59:127-39.
41. Vogels RLC, Oosterman JM, Van Harten B, et al. Profile of cognitive impairment in chronic heart failure. *J Am Geriatr Soc*. 2007;55:1764-70.
42. Harkness K, Demers C, Heckman GA, et al. Screening for cognitive deficits using the montreal cognitive assessment tool in outpatients ≥ 65 years of age with heart failure. *Am J Cardiol*. 2011;107(April):1203-7.
43. Pullicino PM, Wadley VG, McClure LA, et al. Factors contributing to global cognitive impairment in heart failure: results from a population based cohort. *J Card Fail*. 2008;14:290-5.
44. Zuccalà G1, Onder G, Marzetti E, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. *Eur Heart J*. 2005;26:226-33.
45. Petrucci RJ, Wright S, Naka Y, et al. Neurocognitive assessments in advanced heart failure patients receiving continuous-flow left ventricular assist devices. *J Hear Lung Transpl*. 2009;28:542-9.
46. Grimm M, Yeganehfar W, Laufer G, et al. Cyclosporine may affect improvement of cognitive brain function after successful cardiac transplantation. *Circulation*. 1996;94:1339-45.
47. Bornstein RA, Starling RC, Myerowitz PD. Neuropsychological function in patients with end-stage heart failure before and after cardiac transplantation. *Acta Neurol Scand*. 1995;91:260-5.
48. Celutkienė J, Balciunas M, Kablucko D, et al. Challenges of treating acute heart failure in patients with chronic obstructive pulmonary disease. *Card Fail Rev [Internet]*. 2017;3:56-61.
49. Ampadu J, Morley JE. Heart failure cognitive dysfunction. *Int J Cardiol [Internet]*. 2015;178:12-23.
50. Dodson JA, Truong TTN, Towle VR, et al. Cognitive impairment in older adults with heart failure: prevalence, documentation, and impact on outcomes. *Am J Med*. 2013;126(February):120-6.
51. Zuccalà G, Pedone C, Cesari M, et al. The effects of cognitive impairment on mortality among hospitalized patients with heart failure. *Am J Med*. 2003.
52. McLennan SN, Pearson SA, Cameron J, et al. Prognostic importance of cognitive impairment in chronic heart failure patients: Does specialist management make a difference? *Eur J Heart Fail*. 2006;8:494-501.
53. Yancy CW, Jessup M, Bozkurt B, et al., 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/american heart association task force on practice guidelines. *J Am Coll Cardiol [Internet]*. 2013;62:e147-239.
54. Arslanian-engoren C, Giordani BJ, Algase D, et al. Cognitive dysfunction in older adults hospitalized for acute heart failure. *J Card Fail [Internet]*. 2014;20:669-78.
55. Roebuck-Spencer TM, Glen T, Puente AE, et al. Cognitive screening tests versus comprehensive neuropsychological test batteries: a National Academy of Neuropsychology Education Paper. *Arch Clin Neuropsychol*. 2017;32:491-8.